Management of malignant Gastric Outlet Obstruction (mGOO) due to pancreatic cancer in the era of EUS-Gastrojejunostomy: an international practice survey and case vignette study by Pancreas 2000 from the European Pancreatic Club.
Endoscopic ultrasound
Malignant gastric outlet obstruction
Pancreatic cancer
Survey
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
22 Apr 2024
22 Apr 2024
Historique:
received:
03
01
2024
accepted:
17
03
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
22
4
2024
Statut:
aheadofprint
Résumé
Malignant Gastric Outlet Obstruction (mGOO) has been standardly treated by surgical Gastrojejunostomy (S-GJ) or Endoscopic Stenting (ES). Recently, EUS-Gastrojejunostomy (EUS-GJ) has emerged as an alternative, despite its worldwide diffusion is heterogeneous. The aim of this survey was to assess clinical decision-making around mGOO and to explore current opinions regarding EUS-GJ. An online survey, spread through social networks and EPC newsletter, was created exploring opinions regarding indications, contraindications, benefits/risks, availability of mGOO treatments; 2 case vignettes explored clinical decision-making in different scenarios. Overall, 290 pancreatologists from 44 countries responded, of whom 35% surgeons and 65% gastroenterologists. The most common treatment for mGOO was ES (86%), followed by laparoscopic GJ (76%). EUS-GJ was accessible to 59% of respondents, with 10% proficient in this technique. Gold-standard treatment for mGOO varied by specialty; 45% of gastroenterologists preferred ES, 20% EUS-GJ, and 10% surgical GJ, while among surgeons, these were 24%, 8%, and 25%, respectively. A higher annual volume of mGOO treated correlated with increased EUS-GJ adoption and reduced surgical advice. For 51%, EUS-GJ will become the primary treatment for mGOO, notably higher among gastroenterologists and high-volume centers. For 14%, EUS-GJ spread will be limited in the future, or used only when ES fails (19%). Life expectancy, disease stage and patient's frailty are the main decision driver in therapeutic choice, whereas future surgical resectability does not contraindicate any treatment for 75%. EUS-GJ's main advantages were its minimally invasive nature and clinical efficacy, offset by its steep learning curve. This survey revealed significant differences in the management of mGOO, depending on specialties, local expertise and treatment volume, suggesting the lack of standardized algorithms. Life expectancy and patients' frailty are the main decision drivers. Regarding EUS-GJ, its availability remains suboptimal, with learning curve as the main perceived barrier.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant Gastric Outlet Obstruction (mGOO) has been standardly treated by surgical Gastrojejunostomy (S-GJ) or Endoscopic Stenting (ES). Recently, EUS-Gastrojejunostomy (EUS-GJ) has emerged as an alternative, despite its worldwide diffusion is heterogeneous. The aim of this survey was to assess clinical decision-making around mGOO and to explore current opinions regarding EUS-GJ.
METHODS
METHODS
An online survey, spread through social networks and EPC newsletter, was created exploring opinions regarding indications, contraindications, benefits/risks, availability of mGOO treatments; 2 case vignettes explored clinical decision-making in different scenarios.
RESULTS
RESULTS
Overall, 290 pancreatologists from 44 countries responded, of whom 35% surgeons and 65% gastroenterologists. The most common treatment for mGOO was ES (86%), followed by laparoscopic GJ (76%). EUS-GJ was accessible to 59% of respondents, with 10% proficient in this technique. Gold-standard treatment for mGOO varied by specialty; 45% of gastroenterologists preferred ES, 20% EUS-GJ, and 10% surgical GJ, while among surgeons, these were 24%, 8%, and 25%, respectively. A higher annual volume of mGOO treated correlated with increased EUS-GJ adoption and reduced surgical advice. For 51%, EUS-GJ will become the primary treatment for mGOO, notably higher among gastroenterologists and high-volume centers. For 14%, EUS-GJ spread will be limited in the future, or used only when ES fails (19%). Life expectancy, disease stage and patient's frailty are the main decision driver in therapeutic choice, whereas future surgical resectability does not contraindicate any treatment for 75%. EUS-GJ's main advantages were its minimally invasive nature and clinical efficacy, offset by its steep learning curve.
CONCLUSIONS
CONCLUSIONS
This survey revealed significant differences in the management of mGOO, depending on specialties, local expertise and treatment volume, suggesting the lack of standardized algorithms. Life expectancy and patients' frailty are the main decision drivers. Regarding EUS-GJ, its availability remains suboptimal, with learning curve as the main perceived barrier.
Identifiants
pubmed: 38649494
doi: 10.1007/s00464-024-10803-0
pii: 10.1007/s00464-024-10803-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Andreyev HJN, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34(4):503–509
doi: 10.1016/S0959-8049(97)10090-9
pubmed: 9713300
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr Edinb Scotl 36(1):11–48
doi: 10.1016/j.clnu.2016.07.015
Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CHJ, Schwartz MP, Vleggaar FP et al (2010) Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc 71(3):490–499
doi: 10.1016/j.gie.2009.09.042
pubmed: 20003966
van Wanrooij RLJ, Vanella G, Bronswijk M, de Gooyer P, Laleman W, van Malenstein H et al (2022) Endoscopic ultrasound-guided gastroenterostomy versus duodenal stenting for malignant gastric outlet obstruction: an international, multicenter, propensity score-matched comparison. Endoscopy 54(11):1023–1031
doi: 10.1055/a-1782-7568
pubmed: 35325931
Bronswijk M, Vanella G, van Malenstein H, Laleman W, Jaekers J, Topal B et al (2021) Laparoscopic versus EUS-guided gastroenterostomy for gastric outlet obstruction: an international multicenter propensity score–matched comparison (with video). Gastrointest Endosc 94(3):526-536.e2
doi: 10.1016/j.gie.2021.04.006
pubmed: 33852900
van Wanrooij RLJ, Bronswijk M, Kunda R, Everett SM, Lakhtakia S, Rimbas M et al (2022) Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. Endoscopy 54(03):310–332
doi: 10.1055/a-1738-6780
pubmed: 35114696
Kouanda A, Binmoeller K, Hamerski C, Nett A, Bernabe J, Watson R (2021) Endoscopic ultrasound-guided gastroenterostomy versus open surgical gastrojejunostomy: clinical outcomes and cost effectiveness analysis. Surg Endosc 35(12):7058–7067
doi: 10.1007/s00464-020-08221-z
pubmed: 33479837
Vanella G, Dell’Anna G, Capurso G, Maisonneuve P, Bronswijk M, Crippa S et al (2023) EUS-guided gastroenterostomy for management of malignant gastric outlet obstruction: a prospective cohort study with matched comparison with enteral stenting. Gastrointest Endosc 98(3):337-347.e5
doi: 10.1016/j.gie.2023.04.2072
pubmed: 37094692
Teoh AYB, Lakhtakia S, Tarantino I, Perez-Miranda M, Kunda R, Maluf-Filho F et al (2023) Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol 14:S246812532300242X
van der Merwe SW, van Wanrooij RLJ, Bronswijk M, Everett S, Lakhtakia S, Rimbas M et al (2022) Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 54(2):185–205
doi: 10.1055/a-1717-1391
pubmed: 34937098
Ahmed O, Lee JH, Thompson CC, Faulx A (2021) AGA clinical practice update on the optimal management of the malignant alimentary tract obstruction: expert review. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 19(9):1780–1788
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet Lond Engl 370(9596):1453–1457
doi: 10.1016/S0140-6736(07)61602-X
Andreyev HJ, Norman AR, Oates J, Cunningham D (1990) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer Oxf Engl. 34(4):503–509
doi: 10.1016/S0959-8049(97)10090-9
Hamada T, Nakai Y, Isayama H, Sasaki T, Kogure H, Kawakubo K et al (2013) Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate. Surg Endosc 27(4):1243–1248
doi: 10.1007/s00464-012-2585-9
pubmed: 23073685
Kaneko J, Ishiwatari H, Asakura K, Satoh T, Sato J, Ishikawa K et al (2022) Biliary obstruction and pancreatitis after duodenal stent placement in the descending duodenum: a retrospective study. BMC Gastroenterol 22(1):257
doi: 10.1186/s12876-022-02333-7
pubmed: 35597896
pmcid: 9123653
Rizzo GEM, Carrozza L, Quintini D, Ligresti D, Traina M, Tarantino I (2023) A systematic review of endoscopic treatments for concomitant malignant biliary obstruction and malignant gastric outlet obstruction and the outstanding role of endoscopic ultrasound-guided therapies. Cancers 15(9):2585
doi: 10.3390/cancers15092585
pubmed: 37174051
pmcid: 10177271
Vanella G, Bronswijk M, van Wanrooij RL, Dell’Anna G, Laleman W, van Malenstein H et al (2023) Combined endoscopic mAnagement of BiliaRy and gastrIc OutLET obstruction (CABRIOLET Study): a multicenter retrospective analysis. DEN Open 3(1):e132
doi: 10.1002/deo2.132
pubmed: 35898844
Vanella G, Tamburrino D, Capurso G, Bronswijk M, Reni M, Dell’Anna G et al (2022) Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. World J Gastroenterol 28(10):976–984
doi: 10.3748/wjg.v28.i10.976
pubmed: 35431499
pmcid: 8968520